表紙
市場調查報告書

放射性醫藥品的全球市場

Radiopharmaceuticals

出版商 Global Industry Analysts, Inc. 商品編碼 225236
出版日期 內容資訊 英文 589 Pages
商品交期: 最快1-2個工作天內
價格
放射性醫藥品的全球市場 Radiopharmaceuticals
出版日期: 2020年08月01日內容資訊: 英文 589 Pages
簡介

本報告提供全球放射性醫藥品市場相關調查,彙整市場概要和競爭趨勢,產品概要,各地區的趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 序論
    • 現在及未來分析
    • 診斷用放射性醫藥品:壟斷的市場區隔
    • 心臟·腫瘤的放射性醫藥品
    • 新的治療用放射性醫藥品推動全球市場
    • 推動市場的要素
      • 癌症治療的接受性擴大
      • 疾病標靶治療的接受性擴大
      • 重視正確的診斷
      • 分子影像的應用
    • 阻礙市場的要素
      • 嚴格的法律規章指南
      • 全球供不應求
      • 價格敏銳度與競爭
    • 發展中國家趨勢 其他
  • 長期的推動成長要素
    • 癌症發病率上升
    • 各年齡容易罹癌的部位
    • 高齡化
    • 全球心血管疾病統計
  • 產品概要
    • 放射性醫藥品:定義
    • 作用機制
    • 放射性醫藥品的應用
    • 影像診斷的放射性描繪器
    • 治療方法
    • 研究
    • 殺菌
    • 放射性醫藥品的分類
    • 診斷用放射性醫藥品
    • 治療用放射性醫藥品
  • 產品技術創新/引進
  • 近幾年的產業活動
  • 主要企業
    • Actinium Pharmaceuticals, Inc.
    • Alliance Medical
    • Alseres Pharmaceuticals, Inc.
    • Avid Radiopharmaceuticals
    • Bayer HealthCare Pharmaceuticals
    • Bracco Diagnostics, Inc.
    • Cardinal Health, Inc.
    • GE Healthcare
    • Ion Beam Applications S.A
    • Immunomedics, Inc.
    • Jubilant Pharma
    • Lantheus Medical Imaging Inc.
    • Medi-Radiopharma Ltd
    • Nordion, Inc.
    • Peregrine Pharmaceuticals, Inc.
    • PETNET Solutions Inc.
    • Positron Corporation
    • Triad Isotopes, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1889

Sharp Decline in Patient Throughput in Imaging Centers Due to COVID-19 Outbreak Induces a -6.3% Erosion in Demand for Radiopharmaceuticals

The global market for Radiopharmaceuticals is expected to slump by -6.3% in the year 2020 and thereafter recover to reach US$9.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.4% over the analysis period 2020 through 2027. The healthcare supply chain is navigating unchartered, rough waters and struggling to maintain pace with rapidly increasing cases of COVID-19. The pandemic has devastated nearly all segments associated with the healthcare sector, such as medical devices, pharmaceuticals and essential supplies. Healthcare organizations globally are finding it extremely challenging to serve patients while ensuring safety of the medical staff due to marked shortage of supplies as a result of supply chain disruptions. The scenario is complicated by unprecedented scale of the pandemic along with few sourcing options and export restrictions. Amid the COVID-19 outbreak, most companies have reported some form of disruption in their supply chains owing to transportation restrictions. The crisis has also resulted in supply issues associated with radiopharmaceuticals, radioisotopes and kits for therapeutic and diagnostic applications. Nuclear medicine and personalized medicine are heavily reliant on the timely availability of radioisotopes. With air freight restrictions imposed, transport of Mo-99, Tc-99m and other radioisotopes remains impacted during COVID times. NTP Radioisotopes is currently operating at below normal capacity as a result of logistical challenges in South Africa.

While the US accounts for nearly half of the market, it relies on three suppliers of Molybdenum-99 and Technetium-99m. In addition, majority of African nations depend heavily on a single supplier of these radioisotopes that are used for cancer imaging. The COVID-19 outbreak has complicated the scenario owing to ongoing restrictions on flights that have severely disrupted global supply chains, prompting participants to ensure reliable radiopharmaceuticals supply for nuclear medicine. Participants are also facing issues in procuring cold kits for simplifying radiopharmaceutical production. These supply constraints along with shortage of qualified staff has made it challenging for countries to perform tasks such as labeling and quality assurance, hampering complex procedures. There are issues related to particular radiopharmaceuticals. While 18F-FDG is extensively used, non-FDG tracers remained in limited quantities across low-income nations owing to their extensive nature, regulatory restrictions and lack of cyclotron. In addition, various countries are unable to access therapeutic tracers including 123I, 123I-MIBG, and 131I-MIBG due to supply and cost issues. The scenario remains challenging for non-COVID-19 treatment solutions such as medical radioisotopes, which are used in diagnosis and treatment of cancer and certain health conditions by healthcare providers around the world. Every year, millions of patients are administered with radioisotopes for diagnosis and therapeutic purposes. With governments defining the medical radioisotope production facilities as 'essential', production operations continued during the COVID-19 pandemic period. Reactors engaged in production of radioisotopes remained operational in compliance with the relevant IAEA safety standards and in adherence to relevance measures to prevent the effects and spread of COVID-19 disease. Reactors based out of Argentina, Australia, Belgium, Czech Republic, Netherlands, Poland, Russia , USA, and South Africa, account for almost the entire world production of radioisotopes, and the radio compounds produced in these countries are transported worldwide mainly via aerial route.

In the post pandemic period, pent-up demand for cancer and other chronic diseases will push up demand for radioisotopes. The huge unmet needs and the ensuing massive opportunity for imaging technologies and services will benefit long-term growth of radiopharmaceuticals. Growth during this period will continue to benefit from the growing mainstream interest in nuclear medicine, and the development of new radionuclide's for cancer nuclear imaging and internal radiotherapy. A key trend of the pre-virus period that will emerge to spur gains is the shifting of healthcare from fee based systems to value based systems and the resulting new commercial value placed on hybrid molecular imaging techniques which utilize radiopharmaceuticals for accurate and early disease diagnosis. Development of new and innovative radiopharmaceuticals has and will continue to spur the use of PET/CT and SPECT/CT imaging platforms across new clinical areas including cardiology, neurology, orthopedics, pulmonology and oncology. The epidemic spread of cancer will fuel interest in non-invasive tumor receptor imaging thereby pushing up the significance of molecular imaging for its ability to enable better understanding of tumor biology so as to develop more personalized and targeted treatment regimes. Other growth drivers will include growing incidence of cardiovascular diseases and new launch of cardiac radiopharmaceuticals such as flurpiridaz f-18 and ammonia n-13 in the field of cardiovascular disease imaging; expected developments in non-reactor based production of tc-99m in a bid to overcome production challenges of Tc-99m; growing population and healthcare burden; pressing need for effective healthcare solutions; government policy led focus on healthcare infrastructure development; and concerted efforts taken to promote nuclear medicine in emerging Asian economies grappling with the economic challenges of providing affordable healthcare.

Competitors identified in this market include, among others,

  • Actinium Pharmaceuticals Inc.
  • Alliance Medical
  • Alseres Pharmaceuticals Inc.
  • Avid Radiopharmaceuticals
  • Bayer HealthCare, Radiology Division
  • Bracco Diagnostics Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Immunomedics, Inc.
  • Ion Beam Applications SA
  • Jubilant Pharma
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd.
  • Nordion, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • PETNET Solutions Inc.
  • Positron Corporation
  • Triad Isotopes Inc.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to Hinder Nuclear Medicine Procedures in Most Countries
    • EXHIBIT 1: Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in U.S Hospitals
    • Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals Struggling with Seamless Supply of Medical Radioisotopes
    • Nuclear Medicine Services Limp Back to Normality after Easing of COVID-19 Restrictions
    • COVID-19 Presents Generational Opportunity
    • Radiopharmaceuticals: A Prelude
    • Mechanism of Action
    • Global Supply Shortages Continue to Challenge Market Growth
    • EXHIBIT 2: A Glimpse at Mo-99 Processors Worldwide
    • EXHIBIT 3: Nuclear Research Reactor Irradiators Worldwide: A Snapshot
    • Outlook
    • Key Market Drivers
    • Market Restraints
    • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
    • Classification of Radiopharmaceuticals
    • Diagnostic Radiopharmaceuticals: The Dominant Segment
    • Key Drivers
    • Positron Emission Tomography (PET)
    • Major PET Isotopes and their Applications
    • Single Photon Emission Computed Tomography (SPECT)
    • Major Isotopes and their Diagnostic Applications
    • Therapeutic Radiopharmaceuticals
    • Select Isotopes and their Therapeutic Applications
    • Key Drivers
    • Competitive Landscape
    • EXHIBIT 4: Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2019
    • Recent Industry Activity
    • World Brands
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
    • Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
    • Advent of New Radiopharmaceuticals Widen Scope
    • Select New Products
    • Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
    • Select Commercially Available Therapeutic Radiopharmaceuticals
    • PET Eclipses SPECT in Cardiovascular Imaging
    • EXHIBIT 5: Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2019
    • Cardiac Amyloidosis Visualization: A Potential Application for PET
    • Innovative Radiopharmaceuticals to Boost Cardiac Applications
    • EXHIBIT 6: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Application of PET in Drug Development to Expand Opportunities
    • Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
    • Personalized Medicine Drives Nuclear Medicine
    • EXHIBIT 7: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • EXHIBIT 8: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • Rise in Incidence of Neurological Disorders to Drive Growth
    • Rising Cancer Incidence Worldwide Spurs Demand
    • EXHIBIT 9: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 10: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • EXHIBIT 11: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Ageing Population: A Vital Demography
    • EXHIBIT 12: Global Aging Population: Population of 65+ Individuals (in Thousands) by Region for 2019 and 2030
    • EXHIBIT 13: Global Cancer Deaths by Age Group (in %) for 2019
    • Rise in Healthcare Expenditure to Drive Growth
    • EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP
    • EXHIBIT 15: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Relevant Aspects of Radiopharmaceutical Production
    • Regulatory Regime Governing Production and Use of Radiopharmaceuticals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 2: World Historic Review for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 3: World 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 5: World Historic Review for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 6: World 11-Year Perspective for SPECT Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 8: World Historic Review for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 9: World 11-Year Perspective for PET Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 11: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 12: World 11-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 14: World Historic Review for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 15: World 11-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 17: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 18: World 11-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 21: World 11-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 23: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 24: World 11-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 26: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 27: World 11-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 30: World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 32: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 33: World 11-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 35: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 36: World 11-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 39: World 11-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Overview
    • Diagnostic Applications Stimulate Future Growth
    • Demographic Changes Offer Growth Opportunities
    • EXHIBIT 16: US Elderly Population: Expected Growth Rates Over the Years 2005-2025
    • Rising Incidence of Cancer: A Major Growth Driver
    • EXHIBIT 17: Leading Sites of New Cancer Cases in Males: 2020
    • EXHIBIT 18: Leading Sites of New Cancer Cases in Females: 2020
    • Cardiovascular Imaging to Lead Volume Growth
    • Radiopharmaceuticals Usage Strengthens in PET Imaging
    • Radioisotope/Radiopharmaceuticals Supply Scenario
    • Passing of Medicare Diagnostic Radiopharmaceutical Payment Equity Act
    • Market Analytics
    • TABLE 40: USA Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 41: USA Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 42: USA 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 44: USA Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 45: USA 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 47: USA Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 48: USA 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • CANADA
    • Market Overview
    • Efforts on to Address Mo-99 Supply Shortage
    • Market Analytics
    • TABLE 49: Canada Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 50: Canada Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 51: Canada 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 52: Canada Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 53: Canada Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 54: Canada 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 56: Canada Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 57: Canada 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • JAPAN
    • Market Overview
    • Market Analytics
    • TABLE 58: Japan Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 59: Japan Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 60: Japan 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 61: Japan Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 62: Japan Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 63: Japan 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 64: Japan Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 65: Japan Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 66: Japan 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • CHINA
    • Market Overview
    • Market Analytics
    • TABLE 67: China Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 68: China Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 69: China 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 70: China Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 71: China Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 72: China 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 73: China Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 74: China Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 75: China 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • EUROPE
    • Market Overview
    • Market Analytics
    • TABLE 76: Europe Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 77: Europe Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 78: Europe 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2016, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 80: Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 81: Europe 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 82: Europe Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 83: Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 84: Europe 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 85: Europe Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 86: Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 87: Europe 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • FRANCE
    • TABLE 88: France Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 89: France Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 90: France 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 91: France Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 92: France Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 93: France 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 94: France Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 95: France Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 96: France 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • GERMANY
    • TABLE 97: Germany Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 98: Germany Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 99: Germany 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 100: Germany Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 101: Germany Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 102: Germany 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 103: Germany Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 104: Germany Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 105: Germany 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ITALY
    • TABLE 106: Italy Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 107: Italy Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 108: Italy 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 109: Italy Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 110: Italy Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 111: Italy 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 112: Italy Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 113: Italy Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 114: Italy 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 115: UK Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 116: UK Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 117: UK 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 118: UK Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 119: UK Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 120: UK 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 121: UK Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 122: UK Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 123: UK 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SPAIN
    • TABLE 124: Spain Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 125: Spain Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 126: Spain 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 127: Spain Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 128: Spain Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 129: Spain 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 130: Spain Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 131: Spain Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 132: Spain 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • RUSSIA
    • TABLE 133: Russia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 134: Russia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 135: Russia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 136: Russia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 137: Russia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 138: Russia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 139: Russia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 140: Russia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 141: Russia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF EUROPE
    • TABLE 142: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 143: Rest of Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 144: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 145: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 146: Rest of Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 147: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 148: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 149: Rest of Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 150: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ASIA-PACIFIC
    • Market Overview
    • Market Analytics
    • TABLE 151: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 152: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 153: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2016, 2020 & 2027
    • TABLE 154: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 155: Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 156: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 157: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 158: Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 159: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 160: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 161: Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 162: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • AUSTRALIA
    • TABLE 163: Australia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 164: Australia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 165: Australia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 166: Australia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 167: Australia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 168: Australia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 169: Australia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 170: Australia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 171: Australia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • INDIA
    • Market Overview
    • Market Analytics
    • TABLE 172: India Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 173: India Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 174: India 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 175: India Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 176: India Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 177: India 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 178: India Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 179: India Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 180: India 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SOUTH KOREA
    • TABLE 181: South Korea Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 182: South Korea Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 183: South Korea 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 184: South Korea Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 185: South Korea Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 186: South Korea 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 187: South Korea Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 188: South Korea Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 189: South Korea 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 190: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 191: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 192: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 193: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 194: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 195: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 196: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 197: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 198: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • LATIN AMERICA
    • TABLE 199: Latin America Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 200: Latin America Historic Review for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 201: Latin America 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2016, 2020 & 2027
    • TABLE 202: Latin America Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 203: Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 204: Latin America 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 205: Latin America Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 206: Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 207: Latin America 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 208: Latin America Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 209: Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 210: Latin America 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ARGENTINA
    • TABLE 211: Argentina Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 212: Argentina Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 213: Argentina 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 214: Argentina Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 215: Argentina Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 216: Argentina 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 217: Argentina Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 218: Argentina Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 219: Argentina 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • BRAZIL
    • TABLE 220: Brazil Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 221: Brazil Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 222: Brazil 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 223: Brazil Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 224: Brazil Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 225: Brazil 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 226: Brazil Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 227: Brazil Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 228: Brazil 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • MEXICO
    • TABLE 229: Mexico Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 230: Mexico Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 231: Mexico 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 232: Mexico Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 233: Mexico Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 234: Mexico 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 235: Mexico Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 236: Mexico Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 237: Mexico 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 238: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 239: Rest of Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 240: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 241: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 242: Rest of Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 243: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 244: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 245: Rest of Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 246: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • MIDDLE EAST
    • TABLE 247: Middle East Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 248: Middle East Historic Review for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 249: Middle East 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2016, 2020 & 2027
    • TABLE 250: Middle East Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 251: Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 252: Middle East 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 253: Middle East Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 254: Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 255: Middle East 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 256: Middle East Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 257: Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 258: Middle East 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • IRAN
    • TABLE 259: Iran Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 260: Iran Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 261: Iran 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 262: Iran Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 263: Iran Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 264: Iran 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 265: Iran Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 266: Iran Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 267: Iran 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ISRAEL
    • TABLE 268: Israel Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 269: Israel Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 270: Israel 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 271: Israel Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 272: Israel Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 273: Israel 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 274: Israel Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 275: Israel Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 276: Israel 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 277: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 278: Saudi Arabia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 279: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 280: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 281: Saudi Arabia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 282: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 283: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 284: Saudi Arabia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 285: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 286: UAE Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 287: UAE Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 288: UAE 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 289: UAE Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 290: UAE Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 291: UAE 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 292: UAE Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 293: UAE Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 294: UAE 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 295: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 296: Rest of Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 297: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 298: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 299: Rest of Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 300: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 301: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 302: Rest of Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 303: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • AFRICA
    • TABLE 304: Africa Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 305: Africa Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 306: Africa 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 307: Africa Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 308: Africa Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 309: Africa 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 310: Africa Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 311: Africa Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019
    • TABLE 312: Africa 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 77